Related references
Note: Only part of the references are listed.Lentiviral-mediated miRNA against liver-intestine cadherin suppresses tumor growth and invasiveness of human gastric cancer
Qi-Sheng Liu et al.
CANCER SCIENCE (2010)
PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
Marco Falasca
CURRENT PHARMACEUTICAL DESIGN (2010)
A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
Jina Yun et al.
EUROPEAN JOURNAL OF CANCER (2010)
AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway
Ling-Zhi Liu et al.
CANCER RESEARCH (2007)
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt
Fumiyuki Yamasaki et al.
CANCER RESEARCH (2007)
Evi1 is a survival factor which conveys resistance to both TGFb-β and taxol-mediated cell death via PI3K/AKT
Y. Liu et al.
ONCOGENE (2006)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks
Y Pommier et al.
ONCOGENE (2004)
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)
A Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
WL Xia et al.
ONCOGENE (2002)
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α -: A new model for anti-estrogen resistance
RA Campbell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II):: therapeutic implications
W Chu et al.
ONCOGENE (2000)
Share Paper
